![Avram Hershko](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Avram Hershko
Direktor/Vorstandsmitglied bei
The Marine Biological Laboratory
Profil
Avram Hershko has been a Director of IVAX Corp.
since 2003.
He has been a Distinguished Professor since 1998 and Professor, Unit of Biochemistry, Faculty of Medicine since 1980, both at the Technion-Israel Institute of Technology in Haifa, Israel.
He was awarded a Nobel Prize in Chemistry in 2004.
Aktive Positionen von Avram Hershko
| Unternehmen | Position | Beginn |
|---|---|---|
Technion-Israel Institute of Technology
 Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1980 |
The Marine Biological Laboratory
 The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services Provides research and educational services | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Avram Hershko
| Unternehmen | Position | Ende |
|---|---|---|
IVAX LLC
 IVAX LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures & markets branded and generic pharmaceuticals | Direktor/Vorstandsmitglied | 26.01.2006 |
Seed Therapeutics, Inc.
 Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
85
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
IVAX LLC
IVAX LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures & markets branded and generic pharmaceuticals | Health Technology |
Technion-Israel Institute of Technology
Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Marine Biological Laboratory
The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services Provides research and educational services | Commercial Services |
Seed Therapeutics, Inc.
Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang. | Commercial Services |
